 The FDA placed a clinical hold on DiaMedica Therapeutics Incs NASDAQ: DMAC Phase 23 ReMEDy2 trial evaluating DM199 to treat acute ischemic stroke patients. The clinical hold was initiated following the companys pause in patient enrollment and submission. 